Sulfonamidolactam inhibitors of coagulation factor Xa
摘要:
As part of an effort to identify novel backups for previously reported pyrazole-based coagulation Factor Xa inhibitors, the pyrazole 5-carboxamide moiety was replaced by 3-(sulfonylamino)-2-piperidone. This led to the identification of a structurally diverse chemotype that was further optimized to incorporate neutral or weakly basic aryl and heteroaryl P1 groups while maintaining good potency versus Factor Xa. Substitution at the sulfonamide nitrogen provided further improvements in potency and as did introduction of alternate P4 moieties. (C) 2008 Elsevier Ltd. All rights reserved.
SULFONYLAMINOVALEROLAC TAMS AND DERIVATIVES THEREOF AS FACTOR Xa INHIBITORS
申请人:Bristol-Myers Squibb Company
公开号:EP1501798A2
公开(公告)日:2005-02-02
EP1501798A4
申请人:——
公开号:EP1501798A4
公开(公告)日:2006-11-22
US7157470B2
申请人:——
公开号:US7157470B2
公开(公告)日:2007-01-02
US7524863B2
申请人:——
公开号:US7524863B2
公开(公告)日:2009-04-28
[EN] SULFONYLAMINOVALEROLAC TAMS AND DERIVATIVES THEREOF AS FACTOR Xa INHIBITORS<br/>[FR] SULFONYLAMINOVALEROLAC TAMES ET DERIVES DE CES DERNIERS COMME INHIBITEURS DE FACTEUR XA
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2004041776A2
公开(公告)日:2004-05-21
The present application describes sulfonylaminovalerolactams and derivatives thereof of Formula (I), or pharmaceutically acceptable salt forms thereof, wherein ring G is a mono- or bicyclic carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.